“The strategic migration of Quanta System's North American business to Cartessa secures and strengthens our ability to bring our multi-laser platforms and innovative technologies to more aesthetic practices and their patients,” said Paolo Salvadeo, Quanta System CEO & General Manager of El.En SpA
NEW YORK (PRWEB) December 03, 2018
Quanta System announced today an exclusive distribution agreement with Cartessa Aesthetics, an emerging leader in the distribution and marketing of cutting-edge aesthetic devices in the US. Since inception in early 2017, Cartessa has experienced rapid growth, projecting $20MM in sales for 2018. Cartessa’s success can be attributed in-part to the company’s independent business model which allows Cartessa to hand-select best-in-class technologies from across the globe. Their elite product portfolio and boutique support model made Cartessa the top choice for expanding Quanta System’s footprint in the US aesthetics market.
“The strategic migration of our North American business to Cartessa Aesthetics secures and strengthens our ability to bring our multi-laser platforms and innovative technologies to more aesthetic practices and their patients,” said Paolo Salvadeo, CEO of Quanta System SpA and General Manager of El.En SpA. “While Cartessa was founded less than 2 years ago, they have already shown to be a great partner to El.En. Their team, with industry veteran Gabe Lubin at the helm, is destined for continued growth and we are honored to be part of this success."
With more than 100 distributors worldwide and a production facility that spans 150,000 square feet, Quanta System is recognized as the global leader in the development and manufacturing of premium laser technology for surgery, aesthetics and art conservation. “Their innovative designs and world-class multi-laser platforms puts Quanta System in a position to improve patient satisfaction and become a preferred brand amongst providers,” said Gabe Lubin, Founder and CEO of Cartessa Aesthetics. “It has been a pleasure to work with Paolo and we look forward to deepening our relationship with Quanta System and El.En.”
The agreement, signed in Manhattan, New York last week is not the first partnership between Cartessa Aesthetics and El.En., Europe’s leading aesthetic device manufacturer and parent company to Quanta System and DEKA. Quanta System is the manufacturer behind the DenaVe, a 585nm vascular laser introduced earlier this year by Cartessa. The DenaVe has already been hailed as a breakthrough device as it delivers several benefits over traditional technologies. In addition, Cartessa currently distributes three of DEKA’s revolutionary products: Motus AX / AY known for pain-free permanent hair reduction for all skin types, and Punto, a novel CO2 fractional laser.
Girolamo Lionetti, General Manager of Quanta System SpA said, “We have a long history of identifying successful synergies across markets. We anticipate that this is the first step in a long lasting and highly profitable relationship driven by mutual trust and shared visions.”
About Quanta System SpA
Quanta Systems is a 100% Italian company that offers innovative laser systems for surgery, aesthetics, veterinary and art conservation to the global market since 1985. Headquartered in Samarate (Varese, Italy), the company employs 160 people that oversee the entire process of research, development and production of lasers used worldwide and distributed through a network of 110 international distributors. Quanta System is controlled by El.En SpA, the Italian parent company of a high-tech Industrial Group listed on the STAR segment of Borsa Italiana (Italian Stock Exchange – Mid Caps – ELN.MI). Quanta System is the reference partner for Healthcare Facilities, Institutions and Authorities involved in scientific, medical and research projects worldwide.
About Cartessa Aesthetics
Cartessa Aesthetics, LLC sources leading aesthetic medical devices for distribution to dermatologists, plastic surgeons, cosmetic physicians and medical spas. Cartessa selects the most cutting-edge technologies that offer clinically proven efficacy, patient safety, and the best possible investment for patients and professionals. All products within Cartessa’s portfolio are FDA-cleared. For more information visit: http://www.cartessaaesthetics.com